BR9811458A - "solvent system for improved penetration of pharmaceutical compounds" - Google Patents

"solvent system for improved penetration of pharmaceutical compounds"

Info

Publication number
BR9811458A
BR9811458A BR9811458-1A BR9811458A BR9811458A BR 9811458 A BR9811458 A BR 9811458A BR 9811458 A BR9811458 A BR 9811458A BR 9811458 A BR9811458 A BR 9811458A
Authority
BR
Brazil
Prior art keywords
solvent system
pharmaceutical compounds
improved penetration
penetration
compound
Prior art date
Application number
BR9811458-1A
Other languages
Portuguese (pt)
Inventor
Rao Chakradhara
Jue-Chen Liu
Jonas C T Wang
Original Assignee
Johnson & Johnson Consumer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer filed Critical Johnson & Johnson Consumer
Publication of BR9811458A publication Critical patent/BR9811458A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"SISTEMA SOLVENTE PARA PENETRAçãO MELHORADA DE COMPOSTOS FARMACêUTICOS"<D>. é descrita uma composição consistindo de um composto farmacêutico ou droga topicamente ativa e um sistema solvente tamponado capaz de melhorar a penetração de referida droga. O sistema solvente tamponado permite uma quantidade reduzida de composto farmacêutico na composição sem alterar significativamente a eficácia do referido composto.Invention Patent: <B> "SOLVENT SYSTEM FOR IMPROVED PENETRATION OF PHARMACEUTICAL COMPOUNDS" <D>. a composition consisting of a topically active pharmaceutical compound or drug and a buffered solvent system capable of improving the penetration of said drug is described. The buffered solvent system allows a reduced amount of pharmaceutical compound in the composition without significantly altering the effectiveness of said compound.

BR9811458-1A 1997-03-31 1998-03-03 "solvent system for improved penetration of pharmaceutical compounds" BR9811458A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82909197A 1997-03-31 1997-03-31
PCT/US1998/004033 WO1998043673A1 (en) 1997-03-31 1998-03-03 Solvent system for enhanced penetration of pharmaceutical compounds

Publications (1)

Publication Number Publication Date
BR9811458A true BR9811458A (en) 2000-09-19

Family

ID=25253504

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811458-1A BR9811458A (en) 1997-03-31 1998-03-03 "solvent system for improved penetration of pharmaceutical compounds"

Country Status (14)

Country Link
EP (1) EP0971746A1 (en)
JP (1) JP2001518879A (en)
KR (1) KR19980081207A (en)
CN (1) CN1252003A (en)
AR (1) AR012217A1 (en)
AU (1) AU6677698A (en)
BR (1) BR9811458A (en)
CA (1) CA2285368A1 (en)
CO (1) CO5050328A1 (en)
HU (1) HUP0001739A3 (en)
IL (1) IL132096A0 (en)
PL (1) PL335934A1 (en)
WO (1) WO1998043673A1 (en)
ZA (1) ZA982662B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2232855C (en) * 1997-04-10 2007-10-09 Roche Consumer Health (Worldwide) Sa Pharmaceutical formulation
AU5146600A (en) * 1999-05-27 2000-12-18 Procter & Gamble Company, The Topical compositions providing improved treatment of skin or scalp fungal infections
GB0103046D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP5435836B2 (en) * 2003-07-03 2014-03-05 大正製薬株式会社 Antifungal composition for external use
JP4784051B2 (en) * 2003-07-03 2011-09-28 大正製薬株式会社 Antifungal composition for external use that prevents adsorption to the container
DE102005059742A1 (en) 2005-12-13 2007-06-14 Beiersdorf Ag Transparent sunscreen
US20080032994A1 (en) 2006-08-03 2008-02-07 Marcel Borgers Modified azole compounds as antifungal and antibacterial agents
ES2349906T3 (en) * 2007-07-25 2011-01-12 Ixodes Gmbh TOPICAL ANTIBIOTIC COMPOSITION TO PREVENT LYME DISEASE.
CN101820877B (en) * 2007-08-27 2013-09-11 日本农药株式会社 Agent for fungal dermatitis
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
US9839611B2 (en) * 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
AU2014329421B2 (en) 2013-10-03 2018-08-02 Dow Pharmaceutical Sciences, Inc. Stabilized efinaconazole compositions
WO2015077729A2 (en) 2013-11-22 2015-05-28 Dow Pharmaceutical Sciences, Inc. Anti-infective methods, compositions, and devices
CN115745757B (en) * 2022-11-07 2024-04-26 中国人民解放军军事科学院军事医学研究院 Synthesis of liquid-state polyglycol column arene derivative and application of liquid-state polyglycol column arene derivative in transdermal pharmacodynamic molecule slow release

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331137C (en) * 1988-02-29 1994-08-02 Pfizer, Inc. Transdermal flux enhancing compositions
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
CN1106259A (en) * 1994-02-05 1995-08-09 日东制药株式会社 Antiphlogistic and analgesic gel agent for external use containing propanoic acid non steroid pharmaceutical as effective composition

Also Published As

Publication number Publication date
AR012217A1 (en) 2000-09-27
HUP0001739A2 (en) 2000-12-28
KR19980081207A (en) 1998-11-25
CN1252003A (en) 2000-05-03
AU6677698A (en) 1998-10-22
EP0971746A1 (en) 2000-01-19
WO1998043673A1 (en) 1998-10-08
PL335934A1 (en) 2000-05-22
CO5050328A1 (en) 2001-06-27
CA2285368A1 (en) 1998-10-08
JP2001518879A (en) 2001-10-16
ZA982662B (en) 1999-09-30
HUP0001739A3 (en) 2001-04-28
IL132096A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
BR9811458A (en) &#34;solvent system for improved penetration of pharmaceutical compounds&#34;
BR9909565A (en) Bicyclic derivatives of hydroxamic acid
PT1087750E (en) Pharmaceutical formulations for aerosols with two or more active substances
IT1283102B1 (en) THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ESTROGENIC OR PROGESTINIC ACTIVE SUBSTANCE OR OF THEIR MIXTURES
BR0014384A (en) Compounds for the treatment of ischemia
BR9803300A (en) Pharmaceutical formulation.
BR9811249A (en) New formulation for inhalation; showing volumetric density, when poured, from 0.20 to 0.38g / ml, process for preparing formulation and using it
BR9709062A (en) Compound, pharmaceutical composition, and, use of a compound.
BR9810312A (en) Pharmaceutical composition that has marked antitumor activity and / or reduced side effects containing an antitumor agent and a derivative of hydroxy acid
BR9709915A (en) Compound pharmaceutical composition use of the compound and processes for the treatment or prevention of physiological disorders associated with an excess of tachykinins and for the preparation of the compound
BR9807234A (en) Pharmaceutical composition
BR0014818A (en) Bicyclic imidazo-3-yl-amines preparation procedure and drugs containing at least one bicyclic imidazo-3-yl-amines
ES2192234T3 (en) PARENTERAL PHARMACEUTICAL COMPOSITIONS CONTAINING SALTS OF 2-ARILPROPIONIC ACIDS.
ES2149305T3 (en) SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE PROCEDURES.
BR9916575A (en) Pharmaceutical composition of controlled release with tilidine mesylate as active substance
BR9809508A (en) Therapeutic agent for erectile dysfunction
ES2062375T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A ZINC COMPLEX.
KR960006915A (en) Therapeutic composition of pancreatitis
BR9908427A (en) Pharmaceutical compositions and use thereof
DE59914183D1 (en) DISPOSABLE DEVICE FOR A COMPOSITION OF A PHARMACEUTICALLY ACTIVE SUBSTANCE
BR0013582A (en) Selective retinoid agonists for rar
BR9812875A (en) Processes for the treatment of rheumatoid arthritis in a mammal, and for the manufacture of a therapeutic composition for the treatment of rheumatoid arthritis in a mammal, use of a compound, and pharmaceutical composition
BR9707770C1 (en) Tifluzamide with improved efficacy
BR9910201A (en) Transdermal therapeutic system for the use of candesartan
BR9810433A (en) Anthelmintic compositions

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]